<DOC>
	<DOCNO>NCT01387555</DOCNO>
	<brief_summary>This study determine whether JX-594 ( Pexa-Vec ) plus best supportive care effective improve survival best supportive care patient advance Hepatocellular Carcinoma ( HCC ) fail sorafenib .</brief_summary>
	<brief_title>A Phase 2b Study Modified Vaccinia Virus Treat Patients Advanced Liver Cancer Who Failed Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>KEY Diagnosis primary HCC tissue biopsy ( histological/cytological diagnosis ) , clinical diagnosis Previously treat sorafenib ≥ 14 day discontinue sorafenib treatment least 14 day prior randomization due either intolerance radiographic progression NOTE : Sorafenib NOT require recent treatment receive HCC ECOG performance status 0 , 1 2 ChildPugh Class A ; ChildPugh Class B7 without clinically significant ascites Hematocrit ≥30 % Hemoglobin ≥10 g/dL Tumor status : Measurable viable tumor liver injectable imagingguidance ; At least one tumor liver receive prior localregional treatment OR exhibit &gt; 25 % growth viable tumor size since prior localregional treatment . KEY Received sorafenib within 14 day prior randomization Received systemic anticancer therapy sorafenib within 28 day randomization Prior treatment JX594 Platelet count &lt; 50,000 PLT/ mm3 Total white blood cell count &lt; 2,000 cells/mm3 Prior plan organ transplant Known significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication Severe unstable cardiac disease Viable CNS malignancy associate clinical symptom Pregnant nursing infant History inflammatory skin condition ( e.g. , eczema require previous treatment , atopic dermatitis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>liver tumor</keyword>
	<keyword>advanced hcc</keyword>
	<keyword>hepatocellular cancer</keyword>
	<keyword>Jennerex</keyword>
	<keyword>HCC</keyword>
	<keyword>sorafenib</keyword>
	<keyword>sorafenib failure</keyword>
	<keyword>sorafenib intolerant</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Nexavar failure</keyword>
	<keyword>JX594</keyword>
	<keyword>oncolytic virus</keyword>
	<keyword>vaccinia</keyword>
	<keyword>viral therapy</keyword>
	<keyword>JX</keyword>
	<keyword>Biotherapeutics</keyword>
	<keyword>HEP018</keyword>
	<keyword>traverse</keyword>
	<keyword>biologic</keyword>
	<keyword>Pexa-Vec</keyword>
</DOC>